Symptoms and General Pathology

All Conditions

Blood and Lymph Conditions

Nutritional and Metabolic Diseases

Digestive System Diseases

Neoplasms

Immune System Diseases

Mouth and Tooth Diseases

Heart and Blood Diseases

Rare Diseases

Recurrence

Hemorrhage

Constipation

Diarrhea

Lymphadenopathy

Amyloidosis

Nausea

Gastrointestinal Hemorrhage

Immunoglobulin Light-chain Amyloidosis

Purpura

Hepatomegaly

Macroglossia

Signs and Symptoms, Digestive

Proteostasis Deficiencies

Metabolic Diseases

Hemostatic Disorders

Blood Coagulation Disorders

Hematologic Diseases

Skin Manifestations

Lymphatic Diseases

Gastrointestinal Diseases

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Immunoproliferative Disorders

Paraproteinemias

Liver Diseases

Hypertrophy

Pathological Conditions, Anatomical

Tongue Diseases

Mouth Diseases

Stomatognathic Diseases

AL Amyloidosis

Hypoglycemic Agents

All Drugs and Chemicals

Gliclazide

Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

Isatuximab

Laboratory Biomarker Analysis

Emma Scott

This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

PRIMARY OBJECTIVES:

I. To assess the efficacy as measured by the confirmed overall hematologic response rate (partial response or better) of isatuximab in relapsed/refractory systemic light chain (AL) amyloidosis.

SECONDARY OBJECTIVES:

I. To evaluate toxicities in the treatment of relapsed/refractory AL amyloidosis with isatuximab.

II. To evaluate time to hematologic response. III. To evaluate duration of response. IV. To evaluate progression-free survival (PFS). V. To evaluate overall survival (OS).

TERTIARY OBJECTIVES:

I. To evaluate efficacy of isatuximab in relapsed/refractory immunoglobulin amyloid light chain (AL) amyloidosis as measured by organ specific response rates (cardiac, renal, gastrointestinal \[GI\], liver, soft tissue, nerve), in the subset of patients that can be evaluated for organ response.

II. To evaluate time to organ response in the subset of patients that can be evaluated for organ response.

OUTLINE:

Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up within 30 days and then every at least every 6 months for up to 4 years.

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis

Will include partial response, very good partial response and complete response. Hematologic response will be reported with a binomial confidence interval.

Will be evaluated using the Common Terminology Criteria for Adverse Events version 4.0. The maximum grade for each toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.

Organ response will be evaluated in the subset of patients with evaluable organ involvement using current criteria. The proportion of patients with organ response will be estimated as the number of patients with documented organ response out of the number of patients with documented evaluable organ involvement at baseline.

Will be estimated using the Kaplan-Meier method.

National Cancer Institute (NCI)

SWOG Cancer Research Network

Spots Global Cancer Trial Database for macroglossia

Every month we try and update this database with for macroglossia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.